…
Hydreight Technologies Inc. provides operates in the digital health technology sector in the United States. The company develops a proprietary telemedicine service that allows users to book confidential health and wellness, and/or medical services through a mobile application. It also provides consulting and advice in setting up health and wellness services, including assistance with finding experienced advisors in the areas of medical and privacy law, among others; medical liability insurance; pharmaceutical IV programs vetted by duly licensed pharmacists; procedural guides with respect to various services, such as wide ranging IV therapy treatments, GLP1, NAD, Botox, and fillers; and hiring, on-boarding, training, marketing, branding, payroll, and other accounting services. In addition, the company offers an online pharmacy, which allow its network of medical practitioners to purchase pharmacy products from federally regulated pharmacies. Hydreight Technologies Inc. is headquartered in Las Vegas, Nevada.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Public information on Hydreight Technologies Inc (NURS.V) is limited, with filings and disclosures providing little detail about its core operations. If pursuing technology or health‑related commercialization, long‑term growth drivers could include product development, regulatory approvals and market expansion, and investors may find potential upside if management executes these stages.
Key risks include early‑stage execution and financing uncertainty, thin trading liquidity and regulatory or market access obstacles that could materially impair prospects.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Income before tax | -0.41M | -1.94M | -6.00M | -0.52M | -0.23M |
| Net income | -0.41M | -1.94M | -6.00M | -0.53M | -0.23M |
| Selling general administrative | 5.46M | 5.73M | 3.11M | 0.99M | 0.42M |
| Gross profit | 5.70M | 4.96M | 1.84M | 0.64M | 0.32M |
| Reconciled depreciation | 0.18M | 0.11M | 0.04M | 0.00M | - |
| Operating income | 0.29M | -1.47M | -1.96M | -0.44M | -0.23M |
| Interest expense | - | 0.00M | 0.00M | 0.00M | - |
| Tax provision | - | - | 0.00M | 0.01M | 0.00M |
| Interest income | 0.02M | 0.02M | 0.00M | - | - |
| Net interest income | -0.72M | -0.45M | -0.10M | -0.08M | - |
| Total revenue | 16.04M | 11.51M | 4.27M | 1.20M | 0.45M |
| Total operating expenses | 15.75M | 12.97M | 6.23M | 1.64M | 0.68M |
| Cost of revenue | 10.35M | 6.55M | 2.43M | 0.56M | 0.13M |
| Total other income expense net | 0.02M | -0.02M | -3.93M | -0.00M | - |
| Net income from continuing ops | -0.41M | -1.94M | -6.00M | -0.53M | -0.23M |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Total assets | 3.11M | 2.60M | 2.89M | 0.43M | 0.04M |
| Intangible assets | 1.53M | - | - | - | - |
| Total liab | 4.88M | 4.43M | 3.25M | 1.21M | 0.29M |
| Total stockholder equity | -1.77M | -1.83M | -0.36M | -0.78M | -0.25M |
| Capital stock | 7.10M | 6.53M | 6.23M | 0.00M | 0.00M |
| Retained earnings | -9.13M | -8.73M | -6.79M | -0.79M | -0.27M |
| Cash | 1.19M | 1.78M | 2.43M | 0.01M | 0.03M |
| Total current liabilities | 4.04M | 4.41M | 3.23M | 1.20M | 0.29M |
| Total current assets | 1.58M | 2.06M | 2.62M | 0.05M | 0.04M |
| Net receivables | 0.08M | 0.02M | 0.01M | - | - |
| Inventory | 0.00M | 0.10M | 0.10M | 0.00M | - |
| Accounts payable | 1.01M | 1.90M | 0.75M | 0.40M | 0.02M |
| Non current assets total | 1.53M | 0.54M | 0.27M | 0.38M | 0.00M |
| Capital lease obligations | - | 0.00M | 0.02M | 0.00M | - |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Investments | -1.18M | -0.30M | -0.07M | -0.38M | 0.00M |
| Total cash from financing activities | -0.06M | 0.03M | 2.82M | 0.50M | -0.00M |
| Net income | -0.41M | -1.94M | -6.00M | -0.53M | -0.23M |
| Change in cash | -0.60M | -0.65M | 2.43M | -0.03M | 0.03M |
| Begin period cash flow | 1.78M | 2.43M | 0.01M | 0.03M | 0.00M |
| End period cash flow | 1.19M | 1.78M | 2.43M | 0.01M | 0.03M |
| Total cash from operating activities | 0.86M | -0.40M | -0.33M | -0.15M | 0.02M |
| Issuance of capital stock | - | 0.00M | 0.35M | 0.00M | - |
| Depreciation | 0.18M | 0.11M | 0.04M | 0.00M | - |
| Change to inventory | 0.00M | 0.00M | -0.26M | 0.00M | - |
| Change to account receivables | -0.05M | -0.02M | -0.01M | - | - |
| Sale purchase of stock | -0.01M | 0.00M | - | - | - |
| Capital expenditures | 1.18M | 0.21M | 0.07M | 0.38M | 0.00M |
| Change in working capital | 0.37M | 0.98M | 1.30M | 0.38M | 0.25M |
| Stock based compensation | 0.61M | 0.44M | 0.30M | 0.00M | - |
| Other non cash items | - | 0.00M | 3.86M | - | - |
| Free cash flow | -0.33M | -0.61M | -0.40M | -0.53M | 0.02M |
Sector: Healthcare Industry: Health Information Services
|
Stock Name
|
Change
(CAD) |
Price
(CAD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| NURS Hydreight Technologies Inc |
0.07 2.32% |
3.09 | 406.00 | 25.91 | 7.85 | 20.38 | 7.45 | 109.02 |
| ADK Diagnos Inc |
- -% |
0.35 | - | 10.00 | 411.24 | 18.74 | 389.06 | -6.16 |
| NXG NexgenRX Inc. |
- -% |
0.66 | 39.00 | 32.68 | 1.55 | 4.64 | 1.39 | 7.84 |
| PTEC Principal Technologies Inc |
- -% |
0.32 | - | - | 62.75 | 355.42 | 72.08 | -0.81 |
| CHS Comprehensive Healthcare Systems Inc |
- -% |
0.33 | - | - | 4.44 | 13.23 | 3.83 | 26.88 |
Hydreight Technologies Inc. provides operates in the digital health technology sector in the United States. The company develops a proprietary telemedicine service that allows users to book confidential health and wellness, and/or medical services through a mobile application. It also provides consulting and advice in setting up health and wellness services, including assistance with finding experienced advisors in the areas of medical and privacy law, among others; medical liability insurance; pharmaceutical IV programs vetted by duly licensed pharmacists; procedural guides with respect to various services, such as wide ranging IV therapy treatments, GLP1, NAD, Botox, and fillers; and hiring, on-boarding, training, marketing, branding, payroll, and other accounting services. In addition, the company offers an online pharmacy, which allow its network of medical practitioners to purchase pharmacy products from federally regulated pharmacies. Hydreight Technologies Inc. is headquartered in Las Vegas, Nevada.
7251 West Lake Mead Boulevard, Las Vegas, NV, United States, 89128
| Name | Title | Year Born |
|---|---|---|
| Shane Madden | CEO & Director | NA |
| Mr. Joshua Sorin | CFO & Corp. Sec. | NA |
| Mr. Shane Madden | CEO & Director | NA |
| Mr. Joshua Sorin | CFO & Corporate Secretary | NA |
| Mr. Vahid Shababi Shad | Chief Operating Officer | NA |
| Ms. Abbey Vogt | Operations Manager | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.